The aim of this work was to evaluate the efficacy of proanthocyanidins (PACNs) as an adjunctive periodontal therapy in patients with periodontitis. Patients with periodontitis (stage III–IV) were included in this randomised clinical study. Patients with periodontitis received 2 different treatment modalities: minimally invasive nonsurgical therapy only (MINST group) or minimally invasive nonsurgical therapy and subgingival application of collagen hydrogels with PACNs (MINST + PACNs group). Clinical periodontal parameters, that is, pocket probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), were evaluated before treatment and after 8 weeks. Concentrations of immunologic markers, matrix metalloproteinase-3 (MMP-3), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in saliva were assessed at baseline and at 8-week follow-up. Forty-six patients diagnosed with periodontitis were randomised into 2 groups: 23 patients in the MINST group and 23 patients in the MINST + PACNs group received the intended treatment. PACNs combined with MINST resulted in additional statistically significant PPD reduction and CAL gain in moderate periodontal pockets by 0.5 mm (P < .05) on average compared to MINST alone. Additional use of PACNs did not result in additional statistically significant improvement of BOP or PI values. Application of PACNs showed significant reduction of MMP-3 levels in saliva after 8 weeks (P < .05). Adjunctive use of PACNs in MINST resulted in better clinical outcomes for moderate pockets. Additional use of PACNs improved MMP-3 concentration in saliva more than MINST alone. Biochemical analysis revealed that MMP-3 concentration in saliva reflected the periodontal health state.
Background and Objectives: The use of proanthocyanidins (PACNs) alongside standard periodontal treatment procedures can improve periodontal and peri-implant tissue healing. The present study aimed to evaluate the effect of different concentrations of Pelargonium sidoides root extract (PSRE) on periodontal tissue proliferation in comparison with chlorhexidine digluconate (CHX). Materials and Methods: A cell culture study was performed using human gingival fibroblast (HGF-1) and human periodontal ligament fibroblast (HPDLF) lines. The HGF-1 cell line was exposed to CHX (the gold standard treatment in periodontal diseases) and PSRE at concentrations of up to 800 μg/mL, which were compared with negative controls. HGF-1 viability and proliferation were evaluated using fluorescence tests and the PrestoBlue assay, respectively. In addition, the cell proliferation induction ability of PSRE was evaluated by treating HGF-1 and HPDLF cells with PSRE at 25 and 50 μg/mL concentrations and measuring the TGFβ-1 levels using TGFβ-1 ELISA. Results: When comparing the effects of the 25 μg/mL PSRE treatment to the control, a statistically significant difference in HGF-1 cell growth was observed (0.297 ± 0.048 (mean ± SE) and 0.203 ± 0.01, respectively; p = 0.006). The strongest cytotoxic effect on HGF-1 cells was observed with CHX (0.007 ± 0.006, p < 0.001 vs. control). The HGF-1 and HPDLF cells showed statistically significant increases in TGFβ-1 levels when treated with PSRE at 25 and 50 μg/mL compared with the control (352.38 ± 31.32 (mean ± SE) and 330.99 ± 26.53 versus 161.07 ± 15.11 in HGF-1 cells; 397.53 ± 18.1 and 399.91 ± 27.61 versus 137.7 ± 16.54 in HPDLF cells, p < 0.001). Additionally, no negative effects were detected at low PSRE concentrations (less than 100 μg/mL). Conclusions: The results of this study suggested that PACNs may promote HGF-1 and HPDLF cell proliferation. In contrast, CHX showed cytotoxic effects.